hIgDFc-Ig inhibits B cell functions by regulating BCR-Lyn-Syk-NF-κB signaling pathway in treatment for mice with collagen-induced arthritis

Xian‐Zheng Zhang, Xu Li, Dan Mei, Han Wang, Zhongyang Hong, Jinru Ge, le han, Jinling Shu, Xiaoyu Cai, Yue Zhu, Faqin Liang, Qianqian Yu, Yu Tai, feng zhang, Qingtong Wang, Wei Wei, Lingling ZhangAuthorea 2022 · DOI

Abstract Background and purpose: To investigate the effect of hIgDFc-Ig (DG), a new biological agent that competitively binds to IgD receptors, on collagen-induced arthritis and its potential mechanism in regulating B cell antigen-receptor signaling pathway. Experimental approach: DBA1 mice were used to establish collagen-induced arthritis model, three doses of DG were administered by intraperitoneal injection. Clinical assessment of CIA, histopathological examination, flow cytometry, western blotting, immunofluorescence staining, protein chips and other methods were used to evaluate the therapeutic effects. The effects of DG on Daudi cells and IgαIgβ KO Ramos cells stimulated by IgD were also evaluated. Key results: We found that DG has a significant therapeutic effect on CIA mice. DG relieved the clinical assessment of CIA mice and improved the pathology of joints and spleen. In addition, DG can also regulate B cell subsets in the PBMC and spleen of CIA mice, and decrease the level of immunoglobulins. DG can inhibit the BCR signaling activation stimulated by IgD and effect the expression of transcription factors in vitro. In Ramos cells, Igβ or IgαIgβ knockout may reverse the activation of BCR signal pathway under the stimulation of IgD. Conclusion and Implications: DG may play a therapeutic role in CIA mice by regulating BCR-Lyn-Syk-NF-κB signaling pathway, and may be a new promising biological agent for rheumatoid arthritis.

Introduction

Rheumatoid arthritis (RA) is a debilitating autoimmune disease characterized by chronic joint inflammation and bone destruction. While B cells are central players in RA—producing autoantibodies and inflammatory cytokines—most current therapies target broad B cell depletion or specific cytokines like TNF-α. However, many patients do not respond to existing treatments, and broad depletion can lead to immunosuppression. This study explores a more targeted approach: modulating the Immunoglobulin D (IgD) receptor. While the role of IgD in B cell activation is less understood than other antibodies, it is highly expressed on mature B cells. The researchers investigated whether a decoy molecule, hIgDFc-Ig (DG), can competitively bind to these receptors to prevent the signaling cascades that drive RA pathology.

Methods

The study utilized a multi-faceted experimental approach:

  • Animal Model: DBA1 mice were used to establish a Collagen-Induced Arthritis (CIA) model, mimicking human RA.
  • The Therapeutic: The authors synthesized hIgDFc-Ig (DG), a fusion protein consisting of the Fc portion of human IgD.
  • Comparative Analysis: DG's efficacy was compared against established RA drugs, including Etanercept (a TNF inhibitor) and Rituximab (a B cell-depleting antibody).
  • Molecular Techniques: Flow cytometry tracked B cell subsets, while Western blotting and immunofluorescence measured protein phosphorylation. CRISPR-Cas9 was used to create Igα/Igβ knockout Ramos cell lines to pinpoint the drug's interaction with the B cell receptor (BCR) complex.

Key Insights: Competitive Inhibition and Pathway Modulation

The study identifies DG as a competitive antagonist. It binds to the IgD receptor with high affinity ($K_D \approx 1.56 \times 10^{-7}$ M), physically preventing natural IgD from triggering the B cell.

Figure 1: Characterization of IgD receptor expression and DG binding affinity. (C-D) Flow cytometry of B cells. (E) Increased IgDR expression in CIA mice. (G-I) Binding curves and IC50 of DG.

Instead of killing B cells, DG modulates them by inhibiting the BCR-Lyn-Syk-NF-κB cascade. By reducing the phosphorylation of these key messenger proteins, the B cell receives fewer activation signals. In the CIA model, DG treatment helped shift the B cell profile in the spleen and blood back toward a healthy distribution.

Key Results

  • Clinical Improvement: DG significantly reduced the arthritis index and paw swelling in CIA mice in a dose-dependent manner.
  • Tissue Protection: Histological exams showed that DG-treated mice had significantly less cartilage damage, bone erosion, and inflammatory cell infiltration.
  • Cellular Regulation: DG treatment effectively suppressed the over-activation of B cells.
Figure 6: Effect of DG on B and T cell relative absorbance. DG treatment significantly reduces the elevated B cell activation seen in CIA mice, performing comparably to Etanercept and Rituximab.
  • Immunoglobulin Reduction: DG treatment led to a marked decrease in circulating antibodies (IgM, IgE, and various IgG types) that typically drive inflammation in the CIA model.

Conclusion

hIgDFc-Ig (DG) represents a promising new biological agent for rheumatoid arthritis. By regulating the BCR-Lyn-Syk-NF-κB signaling pathway, DG offers a targeted alternative to broad B cell depletion. While preclinical results in the CIA model are encouraging, future work is needed to determine long-term safety and clinical efficacy in human patients.

Summary updated

Abstract

Background and purpose: To investigate the effect of hIgDFc-Ig (DG), a new biological agent that competitively binds to IgD receptors, on collagen-induced arthritis and its potential mechanism in regulating B cell antigen-receptor signaling pathway. Experimental approach: DBA1 mice were used to establish collagen-induced arthritis model, three doses of DG were administered by intraperitoneal injection. Clinical assessment of CIA, histopathological examination, flow cytometry, western blotting, immunofluorescence staining, protein chips and other methods were used to evaluate the therapeutic effects. The effects of DG on Daudi cells and IgαIgβ KO Ramos cells stimulated by IgD were also evaluated. Key results: We found that DG has a significant therapeutic effect on CIA mice. DG relieved the clinical assessment of CIA mice and improved the pathology of joints and spleen. In addition, DG can also regulate B cell subsets in the PBMC and spleen of CIA mice, and decrease the level of immunoglobulins. DG can inhibit the BCR signaling activation stimulated by IgD and effect the expression of transcription factors in vitro. In Ramos cells, Igβ or IgαIgβ knockout may reverse the activation of BCR signal pathway under the stimulation of IgD. Conclusion and Implications: DG may play a therapeutic role in CIA mice by regulating BCR-Lyn-Syk-NF-κB signaling pathway, and may be a new promising biological agent for rheumatoid arthritis.
BibTeX
@misc{zhang2022higdfc,
  author = {Xian‐Zheng Zhang and Xu Li and Dan Mei and Han Wang and Zhongyang Hong and Jinru Ge and le han and Jinling Shu and Xiaoyu Cai and Yue Zhu and Faqin Liang and Qianqian Yu and Yu Tai and feng zhang and Qingtong Wang and Wei Wei and Lingling Zhang},
  title = {{hIgDFc-Ig inhibits B cell functions by regulating BCR-Lyn-Syk-NF-κB signaling pathway in treatment for mice with collagen-induced arthritis}},
  year = {2022},
  doi = {10.22541/au.164865037.76653869/v1},
  howpublished = {Authorea},
}
Figure